Difficulties in Treating a Patient with Inflammatory Bowel Disease

O. Barysheva, K. E. Egorova, A.M. Golubeva, T.V. Kuprina, N. Vezikova, I. M. Marusenko, T.V. Varlamova, D. D. Varlamova
{"title":"Difficulties in Treating a Patient with Inflammatory Bowel Disease","authors":"O. Barysheva, K. E. Egorova, A.M. Golubeva, T.V. Kuprina, N. Vezikova, I. M. Marusenko, T.V. Varlamova, D. D. Varlamova","doi":"10.33978/2307-3586-2023-19-35-74-78","DOIUrl":null,"url":null,"abstract":"Inflammatory bowel diseases (IBD) belong to nosologies, adequate treatment of which makes it possible to achieve clinical and endoscopic remission of diseases. Currently, numerous studies have been conducted confirming the effectiveness of genetically engineered biological drugs (GEBD) in ulcerative colitis and Crohn's disease in adult patients and in children. However, GEBDs are not always effective, there is the primary inefficiency, and due to the formation of neutralizing antibodies, secondary inefficiency may develop, as well as drug intolerance. There is a question of choosing a GEBD for a particular patient. The article presents the clinical case of a young patient with ulcerative colitis and breast cancer, discusses the features of the course and approaches to the treatment of ulcerative colitis, as well as the choice of GEBD, the comorbidity of IBD and oncological diseases.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Effective Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33978/2307-3586-2023-19-35-74-78","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Inflammatory bowel diseases (IBD) belong to nosologies, adequate treatment of which makes it possible to achieve clinical and endoscopic remission of diseases. Currently, numerous studies have been conducted confirming the effectiveness of genetically engineered biological drugs (GEBD) in ulcerative colitis and Crohn's disease in adult patients and in children. However, GEBDs are not always effective, there is the primary inefficiency, and due to the formation of neutralizing antibodies, secondary inefficiency may develop, as well as drug intolerance. There is a question of choosing a GEBD for a particular patient. The article presents the clinical case of a young patient with ulcerative colitis and breast cancer, discusses the features of the course and approaches to the treatment of ulcerative colitis, as well as the choice of GEBD, the comorbidity of IBD and oncological diseases.
治疗炎症性肠病患者时遇到的困难
炎症性肠病(IBD)属于疾病分类,对其进行适当治疗可使疾病在临床和内窥镜下得到缓解。目前,已有大量研究证实,基因工程生物药物(GEBD)对成年和儿童溃疡性结肠炎和克罗恩病有效。然而,基因工程生物药物并不总是有效的,有原发性低效,由于中和抗体的形成,可能会出现继发性低效,以及药物不耐受。这就存在一个为特定患者选择 GEBD 的问题。文章介绍了一位患有溃疡性结肠炎和乳腺癌的年轻患者的临床病例,讨论了溃疡性结肠炎的病程特点和治疗方法,以及 GEBD 的选择、IBD 和肿瘤疾病的合并症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信